Details - Information last confirmed on April 15, 2021
A clinical stage company located in New Jersey developing a first-in class, patented/proprietary, orally-active product, TriGlytza for Type 2 diabetes and metabolic syndrome. Highly motivated owner looking for buyers with a competitive offer. Product concept has been endorsed by leading endocrinologists. Clinical trial has been approved by the U.S. FDA and registered on [ External Link Removed ]: NCT03686657. Patent and Trademark issued by the U.S. Patent and Trademark office (USPTO). Anticipated global market share is over $1.3B. Risk is mitigated by the results from the human proof-of-concept (PoC) clinical research studies. Product can also be developed for diseases such as COVID-19, NASH, PCOS and diabetic neuropathy.
Disclaimer: DealStream has not independently verified any of the information in this listing and makes no warranty as to its accuracy or completeness. This listing does not constitute an offer to sell, solicit or make an offer to buy an investment interest. Offers to sell, or the solicitation of offers to buy, any security can only be made through official offering documents, such as a subscription agreement and private placement memorandum.